Event Details

Third Quarter 2019 Business Highlights

Nov 12, 2019 at 2:00 PM PST

Kodiak management will provide regulatory updates on the company’s “2022 Vision” for KSI-301 following from a successful FDA end-of-phase 2 meeting held on October 30, 2019, and discuss new data from its on-going Phase 1b clinical study of KSI-301 as well as other business highlights for the third quarter ended September 30, 2019.

Supporting Materials